Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Trial Profile

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Haematological malignancies; Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms FLORENCE
  • Sponsors Menarini
  • Most Recent Events

    • 27 Jul 2015 Results published in the Annals of Oncology.
    • 30 Jun 2015 According to a Teijin Pharma media release, Menarini has received approval for febuxostat [Adenuric] in Europe for an expanded indication of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome. The approval is based on positive results from this trial.
    • 02 Jun 2015 Results assessing compliance of sites presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top